

G Caleb Alexander

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5087339/publications.pdf>

Version: 2024-02-01

81
papers

5,138
citations

126907

33
h-index

91884

69
g-index

83
all docs

83
docs citations

83
times ranked

6816
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparison of Treatments for Nonmetastatic Castration-Resistant Prostate Cancer: Matching-Adjusted Indirect Comparison and Network Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2022, 114, 191-202.	6.3	12
2	Effect of reductions in opioid prescribing on opioid use disorder and fatal overdose in the United States: a dynamic Markov model. <i>Addiction</i> , 2022, 117, 969-976.	3.3	7
3	Long-term use of immunosuppressive medicines and in-hospital COVID-19 outcomes: a retrospective cohort study using data from the National COVID Cohort Collaborative. <i>Lancet Rheumatology</i> , The, 2022, 4, e33-e41.	3.9	96
4	Predictors of new persistent opioid use after benign hysterectomy in the United States. <i>American Journal of Obstetrics and Gynecology</i> , 2022, 227, 68.e1-68.e24.	1.3	5
5	Effects of State Opioid Prescribing Laws on Use of Opioid and Other Pain Treatments Among Commercially Insured U.S. Adults. <i>Annals of Internal Medicine</i> , 2022, 175, 617-627.	3.9	23
6	Rejection of Aducanumab (Aduhelm) by the Health Care Community. <i>Medical Care</i> , 2022, 60, 392-393.	2.4	5
7	Real-World Effectiveness of Remdesivir in Adults Hospitalized With Coronavirus Disease 2019 (COVID-19): A Retrospective, Multicenter Comparative Effectiveness Study. <i>Clinical Infectious Diseases</i> , 2022, 75, e516-e524.	5.8	44
8	National Trends in Use of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists by Cardiologists and Other Specialties, 2015 to 2020. <i>Journal of the American Heart Association</i> , 2022, 11, e023811.	3.7	40
9	Thromboprophylaxis in people hospitalized with COVID-19: Assessing intermediate or standard doses in a retrospective cohort study. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, .	2.3	0
10	The Opioid Industry Documents Archive: A Living Digital Repository. <i>American Journal of Public Health</i> , 2022, 112, 1126-1129.	2.7	3
11	Telemedicine and Office-Based Care for Behavioral and Psychiatric Conditions During the COVID-19 Pandemic in the United States. <i>Annals of Internal Medicine</i> , 2021, 174, 428-430.	3.9	23
12	Association Between Chronic Use of Immunosuppressive Drugs and Clinical Outcomes From Coronavirus Disease 2019 (COVID-19) Hospitalization: A Retrospective Cohort Study in a Large US Health System. <i>Clinical Infectious Diseases</i> , 2021, 73, e4124-e4130.	5.8	51
13	Comparison of Systemic Treatments for Metastatic Castration-Sensitive Prostate Cancer. <i>JAMA Oncology</i> , 2021, 7, 412.	7.1	63
14	Comparative effectiveness of biologics and targeted therapies for psoriatic arthritis. <i>RMD Open</i> , 2021, 7, e001399.	3.8	3
15	Ambulatory noninsulin treatment of type 2 diabetes mellitus in the United States, 2015 to 2019. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1843-1850.	4.4	9
16	Evaluation of Aducanumab for Alzheimer Disease. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 1717.	7.4	152
17	Changes in Short-term, Long-term, and Preventive Care Delivery in US Office-Based and Telemedicine Visits During the COVID-19 Pandemic. <i>JAMA Health Forum</i> , 2021, 2, e211529.	2.2	35
18	Primary care physicians' preparedness to treat opioid use disorder in the United States: A cross-sectional survey. <i>Drug and Alcohol Dependence</i> , 2021, 225, 108811.	3.2	20

#	ARTICLE	IF	CITATIONS
19	Use of Hydroxychloroquine, Remdesivir, and Dexamethasone Among Adults Hospitalized With COVID-19 in the United States. <i>Annals of Internal Medicine</i> , 2021, 174, 1395-1403.	3.9	24
20	More than two-dozen prescription drug-based risk scores are available for risk adjustment: A systematic review. <i>Journal of Clinical Epidemiology</i> , 2021, 137, 113-125.	5.0	3
21	The Problem of Aducanumab for the Treatment of Alzheimer Disease. <i>Annals of Internal Medicine</i> , 2021, 174, 1303-1304.	3.9	35
22	Trends in Insulin Types and Devices Used by Adults With Type 2 Diabetes in the United States, 2016 to 2020. <i>JAMA Network Open</i> , 2021, 4, e2128782.	5.9	16
23	Comparative risk of serious infections among real-world users of biologics for psoriasis or psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 285-291.	0.9	61
24	ASHP Foundation Pharmacy Forecast 2020: Strategic Planning Advice for Pharmacy Departments in Hospitals and Health Systems. <i>American Journal of Health-System Pharmacy</i> , 2020, 77, 84-112.	1.0	29
25	An Epidemic in the Midst of a Pandemic: Opioid Use Disorder and COVID-19. <i>Annals of Internal Medicine</i> , 2020, 173, 57-58.	3.9	278
26	Modeling Mitigation Strategies to Reduce Opioid-Related Morbidity and Mortality in the US. <i>JAMA Network Open</i> , 2020, 3, e2023677.	5.9	24
27	Implementation and enforcement of state opioid prescribing laws. <i>Drug and Alcohol Dependence</i> , 2020, 213, 108107.	3.2	21
28	The United States Postal Service: an Essential Public Health Agency?. <i>Journal of General Internal Medicine</i> , 2020, 35, 3699-3701.	2.6	0
29	Use and Content of Primary Care Office-Based vs Telemedicine Care Visits During the COVID-19 Pandemic in the US. <i>JAMA Network Open</i> , 2020, 3, e2021476.	5.9	332
30	Hyperkalemia and Acute Kidney Injury with Spironolactone Use Among Patients with Heart Failure. <i>Mayo Clinic Proceedings</i> , 2020, 95, 2408-2419.	3.0	10
31	Association between sodium-glucose cotransporter 2 (SGLT2) inhibitors and lower extremity amputation: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2020, 15, e0234065.	2.5	59
32	Characteristics of registered clinical trials assessing treatments for COVID-19: a cross-sectional analysis. <i>BMJ Open</i> , 2020, 10, e039978.	1.9	42
33	The Evolving Overdose Epidemic: Synthetic Opioids and Rising Stimulant-Related Harms. <i>Epidemiologic Reviews</i> , 2020, 42, 154-166.	3.5	81
34	Discontinuation of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Chronic Kidney Disease. <i>Mayo Clinic Proceedings</i> , 2019, 94, 2220-2229.	3.0	39
35	Association Between Pharmacy Closures and Adherence to Cardiovascular Medications Among Older US Adults. <i>JAMA Network Open</i> , 2019, 2, e192606.	5.9	27
36	Association between US Pharmacopeia (USP) monograph standards, generic entry and prescription drug costs. <i>PLoS ONE</i> , 2019, 14, e0225109.	2.5	2

#	ARTICLE	IF	CITATIONS
37	Effects of Prescription Drug Insurance on Hospitalization and Mortality: Evidence from Medicare Part D. <i>Journal of Risk and Insurance</i> , 2019, 86, 595-628.	1.6	13
38	Impact of Florida's prescription drug monitoring program and pill mill law on high-risk patients: A comparative interrupted time series analysis. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 422-429.	1.9	29
39	Cardiovascular safety signals with dipeptidyl peptidase-4 inhibitors: <scp>A</scp> disproportionality analysis among high-risk patients. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 660-667.	1.9	12
40	Exposure- and Dose- response Analyses in Dose Selection and Labeling of FDA-approved Biologics. <i>Clinical Therapeutics</i> , 2018, 40, 95-102.e2.	2.5	14
41	Protocol: mixed-methods study to evaluate implementation, enforcement, and outcomes of U.S. state laws intended to curb high-risk opioid prescribing. <i>Implementation Science</i> , 2018, 13, 37.	6.9	25
42	Quality of Prescribing by Physicians, Nurse Practitioners, and Physician Assistants in the United States. <i>Pharmacotherapy</i> , 2018, 38, 417-427.	2.6	41
43	Relationship between high-risk patients receiving prescription opioids and high-volume opioid prescribers. <i>Addiction</i> , 2018, 113, 677-686.	3.3	22
44	Prevalence of Opioid, Gabapentinoid, and NSAID Use in Patients with CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 1886-1888.	4.5	21
45	Efficacy and safety of biosimilar insulins compared to their reference products: A systematic review. <i>PLoS ONE</i> , 2018, 13, e0195012.	2.5	30
46	Moving Addiction Care to the Mainstream - Improving the Quality of Buprenorphine Treatment. <i>New England Journal of Medicine</i> , 2018, 379, 4-6.	27.0	40
47	Healthcare costs and utilization associated with high-risk prescription opioid use: a retrospective cohort study. <i>BMC Medicine</i> , 2018, 16, 69.	5.5	77
48	Association Between Sodium-Glucose Cotransporter 2 Inhibitors and Lower Extremity Amputation Among Patients With Type 2 Diabetes. <i>JAMA Internal Medicine</i> , 2018, 178, 1190.	5.1	120
49	Non-buprenorphine opioid utilization among patients using buprenorphine. <i>Addiction</i> , 2017, 112, 1045-1053.	3.3	22
50	More States Should Regulate Pain Management Clinics to Promote Public Health. <i>American Journal of Public Health</i> , 2017, 107, 240-243.	2.7	31
51	Impact of prescription drug monitoring programs (PDMPs) on opioid utilization among Medicare beneficiaries in 10 US States. <i>Addiction</i> , 2017, 112, 1784-1796.	3.3	91
52	Prescription drug monitoring program design and function: A qualitative analysis. <i>Drug and Alcohol Dependence</i> , 2017, 180, 395-400.	3.2	40
53	Reducing Branded Prescription Drug Prices: A Review of Policy Options. <i>Pharmacotherapy</i> , 2017, 37, 1469-1478.	2.6	10
54	Physician attitudes and experiences with Maryland's prescription drug monitoring program (PDMP). <i>Addiction</i> , 2017, 112, 311-319.	3.3	53

#	ARTICLE	IF	CITATIONS
55	Cardiovascular Risks of Exogenous Testosterone Use Among Men: A Systematic Review and Meta-Analysis. <i>American Journal of Medicine</i> , 2017, 130, 293-305.	1.5	96
56	Effect of Prescription Drug Coupons on Statin Utilization and Expenditures: A Retrospective Cohort Study. <i>Pharmacotherapy</i> , 2017, 37, 12-24.	2.6	18
57	Primary Care Physicians' Knowledge And Attitudes Regarding Prescription Opioid Abuse and Diversion. <i>Clinical Journal of Pain</i> , 2016, 32, 279-284.	1.9	30
58	Bioequivalence of Biosimilar Tumor Necrosis Factor- α Inhibitors Compared With Their Reference Biologics. <i>Annals of Internal Medicine</i> , 2016, 165, 565.	3.9	52
59	Impact of prescription drug monitoring programs and pill mill laws on high-risk opioid prescribers: A comparative interrupted time series analysis. <i>Drug and Alcohol Dependence</i> , 2016, 165, 1-8.	3.2	95
60	Association between exogenous testosterone and cardiovascular events: an overview of systematic reviews. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 943-956.	11.4	92
61	Cardiovascular risks associated with clarithromycin. <i>BMJ</i> , 2016, 352, i23.	6.0	2
62	Effect of a "pill mill" law on opioid prescribing and utilization: The case of Texas. <i>Drug and Alcohol Dependence</i> , 2016, 159, 190-197.	3.2	71
63	Maximizing the Post-Approval Safety of Flibanserin: A Role for Regulators, Clinicians, and Patients. <i>Drug Safety</i> , 2016, 39, 375-380.	3.2	3
64	Impact of abuse-deterrent OxyContin on prescription opioid utilization. <i>Pharmacoepidemiology and Drug Safety</i> , 2015, 24, 197-204.	1.9	34
65	National Trends in the Ambulatory Treatment of Hypertension in the United States, 1997-2012. <i>PLoS ONE</i> , 2015, 10, e0119292.	2.5	16
66	Prescription Drug Abuse. <i>JAMA Internal Medicine</i> , 2015, 175, 302.	5.1	26
67	How Do Payers Respond to Regulatory Actions? The Case of Bevacizumab. <i>Journal of Oncology Practice</i> , 2015, 11, 313-318.	2.5	5
68	Effect of Florida's Prescription Drug Monitoring Program and Pill Mill Laws on Opioid Prescribing and Use. <i>JAMA Internal Medicine</i> , 2015, 175, 1642.	5.1	207
69	The Prescription Opioid and Heroin Crisis: A Public Health Approach to an Epidemic of Addiction. <i>Annual Review of Public Health</i> , 2015, 36, 559-574.	17.4	1,138
70	Trends in the use of buprenorphine by office-based physicians in the United States, 2003-2013. <i>American Journal on Addictions</i> , 2015, 24, 24-29.	1.4	43
71	Most Primary Care Physicians Are Aware Of Prescription Drug Monitoring Programs, But Many Find The Data Difficult To Access. <i>Health Affairs</i> , 2015, 34, 484-492.	5.2	107
72	Ambulatory Treatment of Type 2 Diabetes in the U.S., 1997-2012. <i>Diabetes Care</i> , 2014, 37, 985-992.	8.6	119

#	ARTICLE	IF	CITATIONS
73	Prevalence and treatment of pain in EDs in the United States, 2000 to 2010. American Journal of Emergency Medicine, 2014, 32, 421-431.	1.6	128
74	Capsule Commentary on Faerber et al., Content Analysis of False and Misleading Claims in Television Advertising for Prescription and Nonprescription Drugs. Journal of General Internal Medicine, 2014, 29, 180-180.	2.6	0
75	Impact of a drug utilization review program on high-risk use of prescription controlled substances. Pharmacoepidemiology and Drug Safety, 2014, 23, 419-427.	1.9	20
76	Trends in the use of buprenorphine by office-based physicians in the United States, 2003-2013. American Journal on Addictions, 2014, 24, n/a-n/a.	1.4	1
77	Promotion of Prescription Drugs to Consumers and Providers, 2001-2010. PLoS ONE, 2013, 8, e55504.	2.5	71
78	Ambulatory Diagnosis and Treatment of Nonmalignant Pain in the United States, 2000-2010. Medical Care, 2013, 51, 870-878.	2.4	268
79	Rethinking Opioid Prescribing to Protect Patient Safety and Public Health. JAMA - Journal of the American Medical Association, 2012, 308, 1865.	7.4	79
80	Recommendations to Limit Life Support. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 633-639.	5.6	30
81	Is Treatment Heterogeneity an Achilles' Heel for Comparative Effectiveness Research?. Pharmacotherapy, 2012, 32, 583-585.	2.6	1